Novocure Ltd (NVCR)
NVCR Stock Price Chart
Explore Novocure Ltd interactive price chart. Choose custom timeframes to analyze NVCR price movements and trends.
NVCR Company Profile
Discover essential business fundamentals and corporate details for Novocure Ltd (NVCR) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Devices
IPO Date
2 Oct 2015
Employees
1.61k
Website
https://www.novocure.comCEO
Frank Leonard
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
NVCR Financial Timeline
Browse a chronological timeline of Novocure Ltd corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 23 Jul 2026
EPS estimate is -$0.30, while revenue estimate is $172.72m.
Earnings released on 30 Apr 2026
EPS came in at -$0.62 falling short of the estimated -$0.51 by -21.05%, while revenue for the quarter reached $174.06m , beating expectations by +3.75%.
Earnings released on 26 Feb 2026
EPS came in at -$0.22 surpassing the estimated -$0.41 by +46.34%, while revenue for the quarter reached $174.35m , missing expectations by -0.03%.
Earnings released on 30 Oct 2025
EPS came in at -$0.33 surpassing the estimated -$0.42 by +21.43%, while revenue for the quarter reached $167.20m , missing expectations by -4.13%.
Earnings released on 24 Jul 2025
EPS came in at -$0.36 surpassing the estimated -$0.39 by +7.69%, while revenue for the quarter reached $158.81m , missing expectations by 0.00%.
Earnings released on 24 Apr 2025
EPS came in at -$0.31 surpassing the estimated -$0.47 by +34.04%, while revenue for the quarter reached $154.99m , beating expectations by +0.73%.
Earnings released on 27 Feb 2025
EPS came in at -$0.61 falling short of the estimated -$0.34 by -79.41%, while revenue for the quarter reached $161.27m , beating expectations by +9.28%.
Earnings released on 30 Oct 2024
EPS came in at -$0.28 surpassing the estimated -$0.34 by +17.65%, while revenue for the quarter reached $155.10m , beating expectations by +1.34%.
Earnings released on 25 Jul 2024
EPS came in at -$0.31 surpassing the estimated -$0.40 by +22.50%, while revenue for the quarter reached $150.36m , beating expectations by +4.52%.
Earnings released on 2 May 2024
EPS came in at -$0.36 surpassing the estimated -$0.43 by +16.28%, while revenue for the quarter reached $138.50m , beating expectations by +1.98%.
Earnings released on 22 Feb 2024
EPS came in at -$0.45 surpassing the estimated -$0.53 by +15.09%, while revenue for the quarter reached $133.78m , beating expectations by +1.54%.
Earnings released on 26 Oct 2023
EPS came in at -$0.46 surpassing the estimated -$0.52 by +11.54%, while revenue for the quarter reached $127.32m , missing expectations by -1.53%.
Earnings released on 27 Jul 2023
EPS came in at -$0.54 falling short of the estimated -$0.50 by -8.00%, while revenue for the quarter reached $126.05m , beating expectations by +1.44%.
Earnings released on 4 May 2023
EPS came in at -$0.50 falling short of the estimated -$0.36 by -38.89%, while revenue for the quarter reached $122.18m , missing expectations by -4.01%.
Earnings released on 23 Feb 2023
EPS came in at -$0.36 falling short of the estimated -$0.32 by -12.50%, while revenue for the quarter reached $128.43m , beating expectations by +0.90%.
Earnings released on 27 Oct 2022
EPS came in at -$0.25 surpassing the estimated -$0.30 by +16.67%, while revenue for the quarter reached $131.00m , beating expectations by +0.30%.
Earnings released on 28 Jul 2022
EPS came in at -$0.23 falling short of the estimated -$0.14 by -64.29%, while revenue for the quarter reached $140.87m , beating expectations by +4.37%.
Earnings released on 28 Apr 2022
EPS came in at -$0.04 surpassing the estimated -$0.17 by +76.47%, while revenue for the quarter reached $137.55m , beating expectations by +2.59%.
Earnings released on 24 Feb 2022
EPS came in at -$0.25 falling short of the estimated -$0.10 by -150.00%, while revenue for the quarter reached $133.21m , beating expectations by +0.16%.
Earnings released on 28 Oct 2021
EPS came in at -$0.13 falling short of the estimated -$0.06 by -116.67%, while revenue for the quarter reached $133.61m , beating expectations by +25.70%.
Earnings released on 29 Jul 2021
EPS came in at -$0.14 falling short of the estimated -$0.01 by -1.67k%, while revenue for the quarter reached $133.52m , missing expectations by -5.90%.
NVCR Stock Performance
Access detailed NVCR performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
